Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.33 |
| ▸ | GLA | P06280 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | SRC | P12931 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL543581 | 0.78 | — | — | |
| SCHEMBL4849245 | 0.78 | — | — | |
| SCHEMBL98576 | 0.76 | — | — | |
| SCHEMBL21488385 | 0.73 | POLB (0.44) | ALDH1A1MEN1KMT2ALMNAMAPT | |
| SCHEMBL226310 | 0.72 | ALDH1A1 (0.42) | ALDH1A1KCNN4GAADGAT1MEN1 | |
| SCHEMBL1129794 | 0.72 | ALDH1A1 (0.42) | ALDH1A1KCNN4GAADGAT1MEN1 | |
| SCHEMBL4849252 | 0.72 | ALDH1A1 (0.31) | ALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL2580230 | 0.71 | DGAT1 (0.42) | ALDH1A1KCNN4GAADGAT1MEN1 | |
| SCHEMBL517250 | 0.71 | ALDH1A1 (0.45) | ALDH1A1KCNN4GAADGAT1MEN1 | |
| SCHEMBL10954143 | 0.71 | KCNN4 (0.42) | ALDH1A1KCNN4GAADGAT1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7666898-B2 | Multivalent indole compounds and use thereof as phospholipase-A2 inhibitors | ILYPSA, INC. (US) | 2010-02-23 | — | — | US | disclosed |
| US-7666898-B2 | Multivalent indole compounds and use thereof as phospholipase-A2 inhibitors | ILYPSA, INC. (US) | 2010-02-23 | — | — | US | disclosed |
| US-7666898-B2 | Multivalent indole compounds and use thereof as phospholipase-A2 inhibitors | ILYPSA, INC. (US) | 2010-02-23 | — | — | US | disclosed |
| US-20090318492-A1 | INDOLE COMPOUNDS HAVING C4-ACIDIC SUBSTITUENTS AND USE THEREOF AS PHOSPHOLIPASE-A2 INHIBITORS | ILYPSA, INC. | 2009-12-24 | — | — | US | disclosed |
| US-20090318492-A1 | INDOLE COMPOUNDS HAVING C4-ACIDIC SUBSTITUENTS AND USE THEREOF AS PHOSPHOLIPASE-A2 INHIBITORS | ILYPSA, INC. | 2009-12-24 | — | — | US | disclosed |
| US-20090318492-A1 | INDOLE COMPOUNDS HAVING C4-ACIDIC SUBSTITUENTS AND USE THEREOF AS PHOSPHOLIPASE-A2 INHIBITORS | ILYPSA, INC. | 2009-12-24 | — | — | US | disclosed |
| US-20090306171-A1 | INDOLE COMPOUNDS HAVING C4-AMIDE SUBSTITUENTS AND USE THEREOF AS PHOSPHOLIPASE-A2 INHIBITORS | ILYPSA, INC. | 2009-12-10 | — | — | US | disclosed |
| US-20090306171-A1 | INDOLE COMPOUNDS HAVING C4-AMIDE SUBSTITUENTS AND USE THEREOF AS PHOSPHOLIPASE-A2 INHIBITORS | ILYPSA, INC. | 2009-12-10 | — | — | US | disclosed |
| US-20090306171-A1 | INDOLE COMPOUNDS HAVING C4-AMIDE SUBSTITUENTS AND USE THEREOF AS PHOSPHOLIPASE-A2 INHIBITORS | ILYPSA, INC. | 2009-12-10 | — | — | US | disclosed |
| EP-1960356-A2 | MULTIVALENT INDOLE COMPOUNDS AND USE THEREOF AS PHOSPHOLIPASE-A2 INHIBITORS | Ilypsa, Inc. (US) | 2008-08-27 | — | — | EP | disclosed |
| US-20070135385-A1 | Methyl indoxam; obesity; dietectics; antidiabetic agents; insulin resistance; non-insulin dependent diabetes; glucose intolerance; hypercholesterolemia; hypertriglyceridemia; anticholesterol agents; metabolic disorders; foods;bioavailability; side effect reduction | ILYPSA, INC. | 2007-06-14 | — | — | US | disclosed |
| WO-2007056279-A2 | PHOSPHOLIPASE INHIBITORS, INCLUDING MULTI-VALENT PHOSPHOLIPASE INHIBITORS, AND USE THEREOF, INCLUDING AS LUMEN-LOCALIZED PHOSPHOLIPASE INHIBITORS | ILYPSA, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007056279-A2 | PHOSPHOLIPASE INHIBITORS, INCLUDING MULTI-VALENT PHOSPHOLIPASE INHIBITORS, AND USE THEREOF, INCLUDING AS LUMEN-LOCALIZED PHOSPHOLIPASE INHIBITORS | ILYPSA, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007056280-A1 | INDOLE COMPOUNDS HAVING C4-ACIDIC SUBSTITUENTS AND USE THEREOF AS PHOSPHOLIPASE-A2 INHIBITORS | ILYPSA, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007056280-A1 | INDOLE COMPOUNDS HAVING C4-ACIDIC SUBSTITUENTS AND USE THEREOF AS PHOSPHOLIPASE-A2 INHIBITORS | ILYPSA, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007056281-A2 | MULTIVALENT INDOLE COMPOUNDS AND USE THEREOF AS PHOSPHOLIPASE-A2 INHIBITORS | ILYPSA, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007056281-A2 | MULTIVALENT INDOLE COMPOUNDS AND USE THEREOF AS PHOSPHOLIPASE-A2 INHIBITORS | ILYPSA, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007056275-A2 | INDOLE COMPOUNDS HAVING C4-AMIDE SUBSTITUENTS AND USE THEREOF AS PHOSPHOLIPASE-A2 INHIBITORS | ILYPSA, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| US-4835305-A | Process for the preparation of trifluoroacrylates | HOECHST AKTIENGELSELSCHAFT (DE) | 1989-05-30 | — | — | US | disclosed |
| EP-0287004-A2 | Method for the production of esters of trifluoroacrylic acid | HOECHST AKTIENGESELLSCHAFT (DE) | 1988-10-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318492-A1 | INDOLE COMPOUNDS HAVING C4-ACIDIC SUBSTITUENTS AND USE THEREOF AS PHOSPHOLIPASE-A2 INHIBITORS | PLA2G4A, PLA2G1B, PLA2G4B | ALDH1A1 2297/4885KCNN4 2139/4885GAA 1210/4885 |
| US-20070135385-A1 | Methyl indoxam; obesity; dietectics; antidiabetic agents; insulin resistance; non-insulin dependent diabetes; glucose intolerance; hypercholesterolemia; hypertriglyceridemia; anticholesterol agents; metabolic disorders; foods;bioavailability; side effect reduction | GPR119, INMT, PNLIP | ALDH1A1 2180/4885KCNN4 650/4885GAA 1215/4885 |
| US-20090306171-A1 | INDOLE COMPOUNDS HAVING C4-AMIDE SUBSTITUENTS AND USE THEREOF AS PHOSPHOLIPASE-A2 INHIBITORS | PLA2G1B, PLA2G2E, PLA2G4A | ALDH1A1 2466/4885KCNN4 2024/4885GAA 2519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.